Stockreport
BRIEF-Xbiotech Announces Upcoming Phase 2 Clinical Studies In Dermatology [Reuters]
US:NASDAQ Investor Relations: xbiotech.com/about/investors.html
PDF
BRIEF-Xbiotech Announces Upcoming Phase 2 Clinical Studies In Dermatology | Reuters Reuters Staff 1 Min Read April 16 (Reuters) - XBiotech Inc: * XBIOTECH ANNOUNCES UPCOMING PHASE 2 CLINICAL STUDIES IN DERMATOLOGY * XBIOTECH INC - CONDUCTING FINAL PREPARATIONS FOR STUDY LAUNCH INCLUDING FIRST CLINICAL SITE INITIATION SCHEDULED LATER THIS MONTH Source text for Eikon: Further company coverage: All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays. Š 2018 Reuters. All Rights Reserved.
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | XBIT | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
XBIT alerts
XBIT alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XBIT alerts
High impacting XBiotech, Inc news events
Weekly update
A roundup of the hottest topics
XBIT
NEWS
NEWS
- XBiotech Inc (NASDAQ: XBIT) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating.[MarketBeat]
- XBiotech Inc (NASDAQ: XBIT) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating.[MarketBeat]
- Phase 2 Clinical Trial of Bermekimab Shows Potential New Standard of Care for Treatment of Hidradenitis Suppurativa, Including Significant Pain Reduction without Antibiotics[GlobeNewswire]
- XBiotech up 13% on positive bermekimab data [Seeking Alpha][Seeking Alpha]
- Breakthrough Results from Phase 2 Clinical Trial of Bermekimab in the Treatment of Atopic Dermatitis (AD) to be Presented on March 2, 2019 at American Academy of Dermatology Annual Meeting[GlobeNewswire]
- More
XBIT
SEC Filings
SEC Filings
- 3/15/19 - Form 10-K/A
- 3/14/19 - Form 10-K
- 3/5/19 - Form 4
- XBIT's page on the SEC website
- More